Pathogenesis and Treatment of Graft-Versus-Host Disease After Bone Marrow Transplant

Annual Review of Medicine

Volumn 54, Issue , 2003, Pages 29-52

  Vogelsang, Georgia B ^a   Lee, Linda ^a   Bensen Kennedy, Debra M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Donor lymphocyte infusion; Prednisone; Sclerodermatous; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ACUTE PSYCHOSIS; ANAPHYLAXIS; AVASCULAR NECROSIS; BONE MARROW TRANSPLANTATION; CATARACT; CHRONIC GRAFT REJECTION; CLINICAL FEATURE; DIARRHEA; GASTROINTESTINAL TOXICITY; GINGIVA HYPERTROPHY; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOLOGIC MALIGNANCY; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE DEFICIENCY; KIDNEY FAILURE; LIVER FAILURE; LIVER TOXICITY; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OSTEOPOROSIS; PAIN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEIZURE; SERUM SICKNESS; STEM CELL TRANSPLANTATION; VOMITING; ACUTE DISEASE; CHRONIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; PROGNOSIS; RISK FACTOR;

ACUTE DISEASE; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; RISK FACTORS;

EID: 0037978047     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.54.101601.152339     Document Type: Review

References (89)

1. Barnes DWH, Corp MJ, Loutit JF, Neal FE. 1956. Treatment of murine leukemia with X-rays and homologous bone marrow. BMJ 2:626-27
2. Billingham RE. 1966. The biology of graft-versus-host reactions. Harvey Lect. 62:21-78
3. Erlich HA, Opelz G, Hansen J. 2001. HLA DNA typing and transplantation. Immunity 14:347-56
4. Petersdorf EW, Hansen JA, Martin PJ, et al. 2001. Major- histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N. Engl. J. Med. 345:1794-800
5. Mori M, Beatty PG, Graves M, et al. 1997. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 64:1017-27
6. Goulmy E, Schipper R, Pool J, et al. 1996. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334:281-85
7. Tiberghien P. 2001. Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation. J. Intern. Med. 249:369-77
8. Hill GR, Ferrara JL. 2000. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95:2154-59
9. Johansson JE, Brune M, Ekman T. 2001. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplant. 28:737-42
10. Schmitz H, Fromm M, Bentzel CJ, et al. 1999. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J. Cell Sci. 112(Pt. 1):137-46
11. + secretion in human distal colon driven by proslaglandin E2. Am J. Physiol. Gastrointest. Liver Physiol. 271:G669-G674
12. Radojevic N, McKay DM, Merger M, et al. 1999. Characterization of enteric functional changes evoked by in vivo anti-CD3 T cell activation. Am J. Physiol. Regul. Integr. Comp. Physiol. 276:R715-R723
13. Cooke KR, Gerbitz A, Crawford JM, et al. 2001. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J. Clin. Invest. 107:1581-89
14. Hill GR, Cooke KR, Teshima T, et al. 1998. Inlerleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102:115-23
15. Krijanovski OI, Hill GR, Cooke KR, et al. 1999. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 94:825-31
16. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. 1998. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92:3960-67
17. Antin JH, Lee SJ, Neuberg D, et al. 2002. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 29:373-77
18. Via CS, Shustov A, Rus V, et al. 2001. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J. Immunol. 167:6821-26
19. Hill GR, Teshima T, Gerbitz A, et al. 1999. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J. Clin. Invest. 104:459-67
20. Tsukada N, Kobata T, Aizawa Y, et al. 1999. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 93:2738-47
21. Tamada K, Shimozaki K, Chapoval AI, et al. 2000. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J. Immunol. 164: 4105-10
22. Ogawa S, Nagamatsu G, Watanabe M, et al. 2001. Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host disease. J. Immunol. 167:5741-48
23. Salomon B, Bluestone JA. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225-52
24. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. 1999. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. 162:6368-77
25. Okamura H, Tsutsi H, Komatsu T, et al. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378:88-91
26. Reddy P, Teshima T, Kukuruga M, et al. 2001. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 194:1433-40
27. Okamoto I, Kohno K, Tanimoto T, et al. 2000. IL-18 prevents the development of chronic graft-versus-host disease in mice. J. Immunol. 164:6067-74
28. Williamson E, Garside P, Bradley JA, et al. 1997. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. J. Immunol. 159:1208-15
29. Garside P, Reid S, Steel M, Mowat AM. 1994. Differential cytokine production associated with distinct phases of murine graft-versus-host reaction. Immunology 82:211-14
30. Martin PJ, Schoch G, Fisher L, et al. 1990. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76:1464-72
31. Nevo S, Enger C, Swan V, et al. 1999. Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Transplantation 67:681-89
32. Ponec RJ, Hackman RC, McDonald GB. 1999. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointest. Endosc. 49:612-21
33. Iqbal N, Salzman D, Lazenby AJ, Wilcox CM. 2000. Diagnosis of gastrointestinal graft-versus-host disease. Am. J. Gastroenterol. 95:3034-38
34. Snover DC, Weisdorf SA, Vercellorti GM, et al. 1985. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum. Pathol. 16:387-92
35. Arai S, Lee L, Vogelsang G. 2002. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J. Hematother. Stem Cell Res. 11:215-30
36. Snover DC, Weisdorf SA, Ramsay NK, et al. 1984. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 4:123-30
37. Howell CD, De Victor D, Li J, et al. 1995. Liver T cell subsets and adhesion molecules in murine graft-versus-host disease. Bone Marrow Transplant. 16:139-45
38. Bobe P, Bonardelle D, Reynes M, et al. 1997. Fas-mediated liver damage in MRL hemopoietic chimeras undergoing lpr-mediated graft-versus-host disease. J. Immunol. 159:4197-204
39. Baker MB, Altman NH, Podack ER, Levy RB. 1996. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med. 183:2645-56
40. Hattori K, Hirano T, Miyajima H, et al. 1998. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 91:4051-55
41. Fujii N, Takenaka K, Shinagawa K, et al. 2001. Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 27:1007-10
42. Glucksberg H, Storb R, Fefer A, et al. 1974. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:295-304
43. Ho VT, Soiffer RJ. 2001. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98:3192-204
44. Storb R, Deeg HJ, Whitehead J, et al. 1986. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N. Engl. J. Med. 314:729-35
45. Chao NJ, Snyder DS, Jain M, et al. 2000. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol. Blood Marrow Transplant. 6:254-61
46. Nash RA, Antin JH, Karanes C, et al. 2000. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96:2062-68
47. Hale G, Zhang MJ, Bunjes D, et al. 1998. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92:4581-90
48. Bacigalupo A, Lamparelli T, Bruzzi P, et al. 2001. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98:2942-47
49. Basara N, Gunzelmann S, Willenbacher W, et al. 2001. New immunosuppressants in BMT/GVHD. Transplant. Proc. 33:2220-22
50. Weisdorf D, Haake R, Blazar B, et al. 1990. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75:1024-30
51. Martin PJ, Schoch G, Fisher L, et al. 1991. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 77:1821-28
52. Alcindor T, Gorgun G, Miller KB, et al. 2001. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 98:1622-25
53. Carpenter PA, Appelbaum FR, Corey L, et al. 2002. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99:2712-19
54. Deeg HJ, Blazar BR, Bolwell BJ, et al. 2001. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 98:2052-58
55. Kobbe G, Schneider P, Rohr U, et al. 2001. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNF-alpha antibody. Bone Marrow Transplant. 28:47-49
56. Margolis J, Vogelsang G. 2000. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease. Semin. Oncol. 27:72-77
57. Przepiorka D, Kernan NA, Ippoliti C, et al. 2000. Daclizumab, a humanized antiinterleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95:83-89
58. Fefer A, Sullivan KM, Weiden P, et al. 1987. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog. Clin. Biol. Res. 244:401-8
59. Roush KS, Hillyer CD. 2002. Donor lymphocyte infusion therapy. Transfus. Med. Rev. 16:161-76
60. Collins RH Jr, Shpilberg O, Drobyski WR, et al. 1997. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15:433-44
61. Shimoni A, Nagler A. 2002. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice. Cancer Treat. Res. 110:113-36
62. Kataoka Y, Iwasaki T, Kuroiwa T, et al. 2001. The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. Immunology 103:310-18
63. Hess A, Thoburn C, Chen W, Horwitz L. 2001. Autoreactive T-cell subsets in acute and chronic syngeneic graft-versus-host disease. Transplant. Proc. 33:1754-56
64. Weinberg K, Blazar BR, Wagner JE, et al. 2001. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 97:1458-66
65. Weinberg K, Annert G, Kashyap A, et al. 1995. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol. Blood Marrow Transplant. 1:18-23
66. Parkman R. 1993. Is chronic graft versus host disease an autoimmune disease? Curr. Opin. Immunol. 5:800-3
67. Parkman R. 1998. Chronic graft-versus-host disease. Curr. Opin. Hematol. 5:22-25
68. Weinberg K, Blazar BR, Wagner JE, et al. 2001. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 97:1458-66
69. Deleted in proof
70. Deleted in proof
71. Sullivan KM, Agura E, Anasetti C, et al. 1991. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin. Hematol. 28:250-59
72. Vogelsang GB. 2001. How I treat chronic graft-versus-host disease. Blood 97:1196-201
73. Jacobsohn DA, Montross S, Anders V, Vogelsang GB. 2001. Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. Bone Marrow Transplant. 28:1047-51
74. Ratanatharathorn V, Ayash L, Lazarus HM, et al. 2001. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 28:121-29
75. Thompson AM, Couch M, Zahurak ML, et al. 2002. Risk factors for post-stem cell transplant sinusitis. Bone Marrow Transplant. 29:257-61
76. Sullivan KM, Witherspoon RP, Storb R, et al. 1988. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72:546-54
77. Akpek G, Zahurak ML, Piantadosi S, et al. 2001. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97:1219-26
78. Nevo S, Enger C, Hartley E, et al. 2001. Acute bleeding and thrombocytopenia after bone marrow transplantation. Bone Marrow Transplant. 27:65-72
79. Shulman HM, Sale GE, Lerner KG, et al. 1978. Chronic cutaneous graft-versus-host disease in man. Am. J. Pathol. 91:545-70
80. Sullivan KM, Witherspoon RP, Storb R, et al. 1988. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72:555-61
81. Wingard JR, Piantadosi S, Vogelsang GB, et al. 1989. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74:1428-35
82. Arai S, Vogelsang GB. 2000. Management of graft-versus-host disease. Blood Rev. 14:190-204
83. Margolis J, Vogelsang G. 2000. Chronic graft-versus-host disease. J. Hematother. Stem Cell Res. 9:339-46
84. Mookerjee B, Altomonte V, Vogelsang G. 1999. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant. 24:517-20
85. Marcellus DC, Altomonte VL, Farmer ER, et al. 1999. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 93:66-70
86. Vogelsang GB, Wolff D, Altomonte V, et al. 1996. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant. 17:1061-67
87. Vogelsang GB, Farmer ER, Hess AD, et al. 1992. Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 326:1055-58
88. Gilman AL, Chan KW, Mogul A, et al. 2000. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 6:327-34
89. Kuroiwa T, Kakishita E, Hamano T, et al. 2001. Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J. Clin. Invest. 107:1365-73